{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:26:27Z","timestamp":1787509587031,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005629","name":"Takeda Pharmaceuticals USA Inc Lexington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005629","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.xphs.2021.10.027","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T13:01:52Z","timestamp":1635426112000},"page":"1486-1496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Development of Protein-Specific Analytical Methodologies to Evaluate Compatibility of Recombinant Human (rh)IGF-1\/rhIGFBP-3 with Intravenous Medications Co-Administered to Neonates"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5055-531X","authenticated-orcid":false,"given":"Nazila","family":"Salamat-Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanlu","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Chadwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4618-1615","authenticated-orcid":false,"given":"Christopher","family":"McPherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"38","key":"10.1016\/j.xphs.2021.10.027_bib0001","doi-asserted-by":"crossref","first-page":"5964","DOI":"10.2174\/1381612823666171002114545","article-title":"IGF-1 as a drug for preterm infants: a step-wise clinical development","volume":"23","author":"Hellstrom","year":"2017","journal-title":"Curr Pharm Des"},{"issue":"5","key":"10.1016\/j.xphs.2021.10.027_bib0002","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1542\/peds.112.5.1016","article-title":"Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth","volume":"112","author":"Hellstrom","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.xphs.2021.10.027_bib0003","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ghir.2017.08.004","article-title":"Continuous longitudinal infusion of rhIGF-1\/rhIGFBP-3 in extremely preterm infants: evaluation of feasibility in a phase II study","volume":"36","author":"Hansen-Pupp","year":"2017","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.xphs.2021.10.027_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2018.10.033","article-title":"rhIGF-1\/rhIGFBP-3 in preterm infants: a phase 2 randomized controlled trial","volume":"206","author":"Ley","year":"2019","journal-title":"J Pediatr"},{"issue":"9","key":"10.1016\/j.xphs.2021.10.027_bib0005","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/adc.2009.174268","article-title":"Compatibility of drug infusions in the NICU","volume":"95","author":"Kalikstad","year":"2010","journal-title":"Arch Dis Child"},{"issue":"9","key":"10.1016\/j.xphs.2021.10.027_bib0006","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1097\/CCM.0b013e3181e8adcc","article-title":"Systematic review of physical and chemical compatibility of commonly used medications administered by continuous infusion in intensive care units","volume":"38","author":"Kanji","year":"2010","journal-title":"Crit Care Med"},{"issue":"6","key":"10.1016\/j.xphs.2021.10.027_bib0007","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2146\/ajhp110715","article-title":"Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration","volume":"70","author":"Fox","year":"2013","journal-title":"Am J Health Syst Pharm"},{"issue":"9","key":"10.1016\/j.xphs.2021.10.027_bib0008","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/ajhp\/53.9.1048","article-title":"Compatibility of selected critical care drugs during simulated Y-site administration","volume":"53","author":"Yamashita","year":"1996","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2021.10.027_bib0009","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/jac\/dkg134","article-title":"Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units","volume":"51","author":"Baririan","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.xphs.2021.10.027_bib0010","unstructured":"FDA. CUBICIN\u00ae (daptomycin for injection). Highlights of Prescribing Information. 2003. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021572s038lbl.pdf. Accessed November 8, 2021."},{"issue":"10","key":"10.1016\/j.xphs.2021.10.027_bib0011","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1128\/AAC.34.10.1925","article-title":"Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model","volume":"34","author":"Garrison","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.xphs.2021.10.027_bib0012","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.xphs.2021.10.027_bib0013","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13052-017-0354-z","article-title":"Pattern of drug use among preterm neonates: results from an Italian neonatal intensive care unit","volume":"43","author":"Girardi","year":"2017","journal-title":"Ital J Pediatr"},{"issue":"1","key":"10.1016\/j.xphs.2021.10.027_bib0014","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/2110-5820-2-28","article-title":"Impact of physical incompatibility on drug mass flow rates: example of furosemide-midazolam incompatibility","volume":"2","author":"Foinard","year":"2012","journal-title":"Ann Intensive Care"},{"issue":"4","key":"10.1016\/j.xphs.2021.10.027_bib0015","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1542\/peds.2008-3080","article-title":"Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events","volume":"123","author":"Bradley","year":"2009","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.xphs.2021.10.027_bib0016","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0022-3565(25)32538-3","article-title":"Effect of concentration and time upon inactivation of tobramycin, gentamicin, netilmicin and amikacin by azlocillin, carbenicillin, mecillinam, mezlocillin and piperacillin","volume":"217","author":"Pickering","year":"1981","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.xphs.2021.10.027_bib0017","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1042\/bj1490357","article-title":"The reaction of penicillin with proteins","volume":"149","author":"Corran","year":"1975","journal-title":"Biochem J"},{"issue":"5","key":"10.1016\/j.xphs.2021.10.027_bib0018","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.2042-7158.1982.tb04712.x","article-title":"Reaction of ampicillin with serum albumin to produce penicilloyl-protein conjugates and a piperazinedione","volume":"34","author":"Bundgaard","year":"1982","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.xphs.2021.10.027_bib0019","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jpba.2012.04.010","article-title":"Short-term stability studies of ampicillin and cephalexin in aqueous solution and human plasma: application of least squares method in Arrhenius equation","volume":"73","author":"do Nascimento","year":"2013","journal-title":"J Pharm Biomed Anal"},{"issue":"8","key":"10.1016\/j.xphs.2021.10.027_bib0020","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.2042-7158.1975.tb09510.x","article-title":"Chemical reactions involved in penicillin allergy: kinetics and mechanism of penicillin aminolysis","volume":"27","author":"Tsuji","year":"1975","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2021.10.027_bib0021","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1523-1747.1998.00122.x","article-title":"Molecular features of penicillin allergy","volume":"110","author":"Weltzien","year":"1998","journal-title":"J Invest Dermatol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921005608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921005608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:38:41Z","timestamp":1758361121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354921005608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0022354921005608"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2021.10.027","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of Protein-Specific Analytical Methodologies to Evaluate Compatibility of Recombinant Human (rh)IGF-1\/rhIGFBP-3 with Intravenous Medications Co-Administered to Neonates","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2021.10.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}